We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Optimized CRISPR/CAS9 Delivery for Disease Model Generation
Product News

Optimized CRISPR/CAS9 Delivery for Disease Model Generation

Optimized CRISPR/CAS9 Delivery for Disease Model Generation
Product News

Optimized CRISPR/CAS9 Delivery for Disease Model Generation


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Optimized CRISPR/CAS9 Delivery for Disease Model Generation"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

AMSBIO has launched DNA-In® CRISPR – an innovative transfection reagent that simplifies and accelerates genome editing using large plasmids and difficult-to-transfect cells for life science researchers generating disease models.

Since its emergence, CRISPR-Cas9 technology has been rapidly adopted as a mainstream approach for performing genetic manipulation. This powerful tool has transformed the process of generating “footprint-free” cellular models for studying genetic diseases.

Using this approach, researchers can easily generate disease-relevant isogenic models to determine the impact of correcting or introducing disease-relevant mutations on cellular phenotypes in a tissue-appropriate context. However, problems have remained with certain cell types that are more resistant to transfection and for larger plasmids.

DNA-In® CRISPR has been specially formulated to enable highly efficient transfection of large plasmids (containing CAS9, guide-RNAs and reporter cassettes) particularly when using hard-to-transfect cell types. The reagent is fully chemically-defined and animal component-free leading to increased reliability and low cell toxicity.

This makes it ideally suited for many applications, including use in pre-clinical investigations, giving researchers a regulatory head start in their hunt for new therapeutics. DNA-In® CRISPR is a valuable new addition to the human and mouse genome editing kits and custom genome editing services offered by AMSBIO to quickly and simply generate disease models.

Advertisement